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Editorial
Should Catheter Ablation Be Indicated Only
for Symptom-Relief of AF?
Atrial ﬁbrillation (AF) is the most common arrhythmia, particularly in seniors, with an
incidence of 4% after the age of 65 with the ﬁgure doubling with every 10 years of age.
Strong associations are known between AF and cerebral embolism/stroke, all types of
dementia, heart failure and increased mortality.1–3) Persistence of left atrial (LA) volume
and pressure overloading during AF due to loss of atrial contraction, shortened diastolic
ventricular ﬁlling and atrio-ventricular valvular regurgitation leads to atrial anatomical and
electrical remodeling which further facilitates persistence of AF.4) Canadian Registry of AF
reported that the probability of progression of paroxysmal AF (PAF) to chronic AF (CAF)
(deﬁned as AF on 2 consecutive electrocardiograms separated by  1 week) was 8.6% by 1
year.5) This malignant cycle should be interrupted immediately by restoration and long-
lasting maintenance of sinus rhythm (SR).
New on-treatment analysis of the AFFIRM study revealed that presence of SR was
associated with a 47% reduction of death and use of antiarrhythmic drugs (AAD) was
associated with signiﬁcant increase of mortality by 49%.6) This suggests favorable AAD
eﬀect for AF termination might be oﬀset by its potentially life-threatening adverse eﬀects,
and minimally invasive non-pharmacological treatment without acceptable risks, i.e.
catheter ablation (CA), must be considered ﬁrst-line therapy. Superiority of catheter
ablation (CA) to AAD in AF rhythm control has been shown by recent meta-analyses. The
recent meta-analysis of randomized, controlled trials comparing pulmonary vein isolation
and medical therapy by Piccini et al7) showed markedly higher AF-free survival rate at 1
year in CA (77% vs 29%). According to another meta-analysis by Calkins et al,8) multiple
CA showed higher eﬃcacy of CA (71% vs 52%) and also a lower rate of adverse eﬀects
(5% vs 30%).
As the above shows, CA appears to have an acceptable eﬃcacy and risk of major
complication without any equivalent minimally invasive alternative therapy for treatment of
AF. However, HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical
Ablation of AF9) published in 2007 stated that the primary selection of CA is symptomatic
AF refractory or intolerant to at least one Class 1 or 3 AAD, and recent ESC guidelines10)
published in 2010 also stated CA as ﬁrst-line therapy is a Class IIb recommendation for
patients with paroxysmal AF with no or minimal heart disease, who remain highly
symptomatic despite rate control and who reject AAD therapy, otherwise for drug-
refractory and symptomatic paroxysmal and persistent AF have second-line indication with
Class IIa and IIb recommendation, respectively.
In these guidelines, CA is oﬃcially unjustiﬁable for asymptomatic AF because of the
potential risk of major complications, even if their incidences are recognized to be very low.
However, there is increasing evidence that restoration and maintenance of SR confers
beneﬁts as a consequence of reverse electrical and anatomical remodeling of the atrium and
ventricle.
The ongoing CABANA (Catheter Ablation vs Antiarrhythmic Drug therapy for AF) Trial
conducted by Packer DL et al,11) which is designed to investigate the impact of CA for AF
on survival with a primary endpoint of all-cause mortality, a planned recruitment of 3000
patients and a follow-up period of 3.5 years, might be anticipated to show evidence of CA
as a promising ﬁrst-line therapy for AF.
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